Evidence map›Paper›PMID 39107478›Full record

ArticleGenes and immunity2025

Innate immune dynamics in the context of multisite EGFR mutations in lung adenocarcinoma.

Yuan Peng, Chuan Zeng, Rongxin Liao, Lu Shen, Yan Zhou, Zhenzhou Yang

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Genes and immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuan Peng *Department of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China.ORCID 0000-0001-9563-9568
Chuan Zeng *Department of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China.
Rongxin LiaoDepartment of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China.
Lu ShenGeneplus-Beijing, Beijing, 102206, China.
Yan ZhouDepartment of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China. zhouyan@hospital.cqmu.edu.cn.
Zhenzhou YangDepartment of Cancer Center, Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China. yangzz@cqmu.edu.cn.ORCID 0000-0003-2496-1992

Funding

China Postdoctoral Science Foundation 2022T150777Chongqing Postdoctoral Science Foundation 2021XM1028
6 · The paper itself

Abstract

Based on favorable outcomes and decreased propensity for lymph node and distant metastasis, multiple ground-glass nodules (GGNs) are now predominantly recognized as early-stage primary independent lung cancer. In this study, we discuss a case involving a patient with reoperative multifocal GGNs who was ultimately diagnosed with early multiple intrapulmonary metastases and multifocal primary lung cancers. This patient exhibited multisite epidermal growth factor receptor (EGFR) mutations, including the classical L858R, exon 19 deletion and the rare V834L variant. Despite a high tumor burden and the presence of various EGFR driver mutations, the patient experienced prolonged dormancy and exceptionally slow lesion growth, even without any systemic treatment. Our research indicates that the patient's immune response against the tumor remained robust throughout the disease course. Furthermore, we found that pathways associated with integrin-mediated cell extracellular matrix adhesion played a role in activating her innate immune responses and regulating tumor dormancy. Our findings suggest that the interplay between cancer cell mutations and the tumor microenvironment (TME) phenotype during tumor evolution contributed to this patient's prolonged survival. Integrating these aspects for lung tumor stratification is expected to improve predictions of growth potential and aid in clinical decision making.

Indexed as

Adenocarcinoma of LungErbB ReceptorsImmunity, InnateLung NeoplasmsHumansMutationTumor MicroenvironmentEGFR protein, humanErbB Receptors

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.